Key Takeaway: Travere Therapeutics has been awarded the title of Overall Biopharma Company of the Year by the 2023 Biotech Breakthrough Awards. This recognition is based on the company's innovative contributions to the biotech field. The awards celebrate companies that have made significant advancements in biotechnology.
Price reaction · baseline $5.77 (2023-11-13T17:43:00.000Z) · hit during market hours · clean, no other TVTX news in the window
day 0 close · peak
-1.2%
Market Sentiment Analysis
POSITIVE FACTORS
Travere Therapeutics recognized for innovation in biotech.
Award highlights the company's contributions to the industry.
Recognition as Overall Biopharma Company of the Year.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+79%
120-day peak, hindsight
Typical move
4.7%
average across 9 past catalysts
Lead asset
sparsentan
Phase 3 · Immunoglobulin A Nephropathy
Full Press Release Details
Monday, November 13, 2023 —We were recognized as Overall Biopharma Company of the Year by the 2023 Biotech Breakthrough Awards. Companies awarded the title are judged based on the innovation they bring to the field of biotech. Read the full list of the 2023 winners .
Frequently Asked Questions
What award did Travere Therapeutics receive?
Travere Therapeutics was recognized as Overall Biopharma Company of the Year.
What criteria were used for the award?
Companies are judged based on their innovation in the biotech field.
When was the award announced?
The award was announced on November 13, 2023.
What do the Biotech Breakthrough Awards celebrate?
The awards celebrate significant advancements in biotechnology.